Bent Jakobsen

 Bent Jakobsen
Bent Jakobsen
Scientific Co-Founder

Presentations at Drug Discovery 2015

Thu3  Sep03:30pm(30 mins)
Fine-Tuned T Cell Receptors for Cancer Immunotherapy

Session: New Biological Drugs & Technologies
Room: To be announced

Profile of Bent Jakobsen

Dr Bent Jakobsen is the scientific co-founder of Adaptimmune, focused on the use of T cell therapy to treat cancer. Adaptimmune traces its roots back to Avidex, founded by Bent in 1999 as a spin-out from the University of Oxford, whilst at the Institute of Molecular Medicine (IMM). Bent was head of the Immune Receptor Group at the IMM from 1993 to July 2000. Avidex was acquired by Medigene AG in October 2006 and, in early 2008, Adaptimmune was formed.
Please login to send a Private Message

Hosted By
The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Find us on Facebook Follow us on Twitter

Get the App
Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
iPhone App
Android App
Eventflo Home
copyright ELRIG, eventflo, Labhoo Ltd 2018